Literature DB >> 27545647

Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure.

Saba Haddad1,2, Yong Wang1,2, Bruno Galy3,4, Mortimer Korf-Klingebiel1,2, Valentin Hirsch1,2, Abdul M Baru1,2, Fatemeh Rostami1,2, Marc R Reboll1,2, Jörg Heineke2, Ulrich Flögel5, Stephanie Groos6, André Renner7, Karl Toischer8, Fabian Zimmermann9, Stefan Engeli10, Jens Jordan10, Johann Bauersachs2, Matthias W Hentze3, Kai C Wollert1,2, Tibor Kempf1,2.   

Abstract

Aims: Iron deficiency (ID) is associated with adverse outcomes in heart failure (HF) but the underlying mechanisms are incompletely understood. Intracellular iron availability is secured by two mRNA-binding iron-regulatory proteins (IRPs), IRP1 and IRP2. We generated mice with a cardiomyocyte-targeted deletion of Irp1 and Irp2 to explore the functional implications of ID in the heart independent of systemic ID and anaemia. Methods and results: Iron content in cardiomyocytes was reduced in Irp-targeted mice. The animals were not anaemic and did not show a phenotype under baseline conditions. Irp-targeted mice, however, were unable to increase left ventricular (LV) systolic function in response to an acute dobutamine challenge. After myocardial infarction, Irp-targeted mice developed more severe LV dysfunction with increased HF mortality. Mechanistically, the activity of the iron-sulphur cluster-containing complex I of the mitochondrial electron transport chain was reduced in left ventricles from Irp-targeted mice. As demonstrated by extracellular flux analysis in vitro, mitochondrial respiration was preserved at baseline but failed to increase in response to dobutamine in Irp-targeted cardiomyocytes. As shown by 31P-magnetic resonance spectroscopy in vivo, LV phosphocreatine/ATP ratio declined during dobutamine stress in Irp-targeted mice but remained stable in control mice. Intravenous injection of ferric carboxymaltose replenished cardiac iron stores, restored mitochondrial respiratory capacity and inotropic reserve, and attenuated adverse remodelling after myocardial infarction in Irp-targeted mice but not in control mice. As shown by electrophoretic mobility shift assays, IRP activity was significantly reduced in LV tissue samples from patients with advanced HF and reduced LV tissue iron content. Conclusions: ID in cardiomyocytes impairs mitochondrial respiration and adaptation to acute and chronic increases in workload. Iron supplementation restores cardiac energy reserve and function in iron-deficient hearts. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2016. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  31P-Magnetic resonance spectroscopy; Energy metabolism; Extracellular flux analysis; Heart failure; Iron deficiency

Mesh:

Substances:

Year:  2017        PMID: 27545647     DOI: 10.1093/eurheartj/ehw333

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  48 in total

Review 1.  Iron deficiency as therapeutic target in heart failure: a translational approach.

Authors:  Constantinos Bakogiannis; Alexandros Briasoulis; Dimitrios Mouselimis; Anastasios Tsarouchas; Nikolaos Papageorgiou; Christodoulos Papadopoulos; Nikolaos Fragakis; Vassilios Vassilikos
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

Review 2.  Mitochondrial membrane transporters and metabolic switch in heart failure.

Authors:  Vikas Kumar; T R Santhosh Kumar; C C Kartha
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

Review 3.  Progress in heart failure treatment in Germany.

Authors:  Mark Luedde; Martina E Spehlmann; Norbert Frey
Journal:  Clin Res Cardiol       Date:  2018-07-02       Impact factor: 5.460

Review 4.  Towards Holistic Heart Failure Management-How to Tackle the Iron Deficiency Epidemic?

Authors:  Lucas N L Van Aelst; Dominiek Mazure; Alain Cohen-Solal
Journal:  Curr Heart Fail Rep       Date:  2017-08

Review 5.  In-depth review: is hepcidin a marker for the heart and the kidney?

Authors:  Rengin Elsurer Afsar; Mehmet Kanbay; Avsin Ibis; Baris Afsar
Journal:  Mol Cell Biochem       Date:  2021-05-04       Impact factor: 3.396

6.  Unravelling the molecular basis for cardiac iron metabolism and deficiency in heart failure.

Authors:  Pavel Zhabyeyev; Gavin Y Oudit
Journal:  Eur Heart J       Date:  2017-02-01       Impact factor: 29.983

7.  Heme as a target for protection against doxorubicin-induced apoptosis in H9c2 cardiomyocytes.

Authors:  Na Liu; Liangqiang Zou; Mei Hu; Man Zhang
Journal:  Cell Stress Chaperones       Date:  2019-11-18       Impact factor: 3.667

Review 8.  Improving Postdischarge Outcomes in Acute Heart Failure.

Authors:  Ovidiu Chioncel; Sean P Collins; Andrew P Ambrosy; Peter S Pang; Elena-Laura Antohi; Vlad Anton Iliescu; Aldo P Maggioni; Javed Butler; Alexandre Mebazaa
Journal:  Am J Ther       Date:  2018 Jul/Aug       Impact factor: 2.688

9.  Changes in myocardial iron content following administration of intravenous iron (Myocardial-IRON): Study design.

Authors:  Gema Miñana; Ingrid Cardells; Patricia Palau; Pau Llàcer; Lorenzo Fácila; Luis Almenar; Maria Pilar López-Lereu; Jose V Monmeneu; Martina Amiguet; Jessika González; Alicia Serrano; Vicente Montagud; Raquel López-Vilella; Ernesto Valero; Sergio García-Blas; Vicent Bodí; Rafael de la Espriella-Juan; Juan Sanchis; Francisco J Chorro; Antoni Bayés-Genís; Julio Núñez
Journal:  Clin Cardiol       Date:  2018-06-05       Impact factor: 2.882

Review 10.  Balance of cardiac and systemic hepcidin and its role in heart physiology and pathology.

Authors:  Driton Vela
Journal:  Lab Invest       Date:  2017-10-23       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.